• Diabetes Case Shows Pitfalls of Treatment Rules Tuesday, 18 Aug 2009 | 11:32 AM ET

    It sounds like a simple idea for improving health care: draw up guidelines on how best to treat a particular illness and then pay doctors to follow them. That strategy, which some insurers and health plans already employ, has been embraced during the health care debate by some lawmakers in Congress who want to extend it more broadly.

  • On Gaining Access To Drugs & To Pfizer's CEO Friday, 14 Aug 2009 | 10:00 AM ET

    Before I go on vacation for a week I wanted to close the loop and offer some random thoughts on a few things.

  • The FDAA: Food Drug & Accounting Administration Thursday, 13 Aug 2009 | 12:18 PM ET

    Amid the ongoing healthcare reform brouhaha, pharma stocks are getting buffeted.

  • Regis Rages Against Pfizer Wednesday, 12 Aug 2009 | 12:47 PM ET
    USC football

    OK. I have to put aside the fact that he went to Notre Dame and is a diehard Fighting Irish fan (Go 'SC!), but Regis' trademark rant against Pfizer on "Fast Money" yesterday is too good not to blog it.

  • Dendreon: From Data To A Deal? Tuesday, 11 Aug 2009 | 3:35 PM ET

    For years the Dendreon saga was centered around the controversy over whether its prostate cancer treatment worked or not. Well, now that we know the answer to that question the focus has turned to potential FDA approval of the therapeutic vaccine and the company's ability to make it and master the unique treatment process.

  • The House version of a Health Care overhaul bill will not stand up well in the August heat. It makes for scary reading and if the powers that be could have muscled it through it wouldn't be hanging in the wind for all of us to take shots at it. But there it is and it makes for head scratching moments. My friend, Sydney Williams, who writes one of the best investment letters I get to read, passed along some highlights that were extracted by a buddy of his, Peter Fleckenstein.

  • Avanir's Not A Laughing Stock Tuesday, 11 Aug 2009 | 10:31 AM ET

    I know it's trite and cliche, but I learn something new almost every day on this beat. Take pseudobulbar affect. I'd never heard of it before. I had to Google it when I got a press release late yesterday announcing that Avanir Pharmaceuticals was going to unveil late-stage test results on a drug for it this morning.

  • Pee Is For Pharma, Pfizer & Profits Monday, 10 Aug 2009 | 3:02 PM ET
    Pharma Stocks

    Critics have been saying for years that big pharma's been pi..., er, throwing away money on relatively unproductive research and development of new drugs. But a new study shows urine could eventually provide a new revenue stream.

  • Chadwick: What's Really Taboo on Capitol Hill Monday, 10 Aug 2009 | 10:48 AM ET

    Remember 1993 and health care?  It was doomed because Americans did not want Big Government running one more part of their lives.  Why?  Because Government doesn’t do things very well – it’s as simple as that. 

  • The Novartis Attacks, Dash And Your Emails Friday, 7 Aug 2009 | 3:39 PM ET
    Vasella home in flames.

    The London “Daily Mail” has published photos of the flames and aftermath at the Austrian vacation home of Novartis CEO Dr. Daniel Vasella. The arsonists claim to have used nearly 16 gallons of gasoline to ignite the blaze. It was reportedly set at 3:30 in the morning.

  • The Novartis Attackers Reveal Themselves Thursday, 6 Aug 2009 | 2:15 PM ET
    Daniel Vasella's Hunting House.

    On this website for something called "Bite Back" magazine a group identifying itself as MFAH Austria is claiming responsibility for the recent attacks on Swiss drugmaker Novartis and its employees, including CEO Dr. Daniel Vasella.

  • White House Affirms Deal on Drug Cost Thursday, 6 Aug 2009 | 12:15 PM ET

    Pressed by industry lobbyists, White House officials on Wednesday assured drug makers that the administration stood by a behind-the-scenes deal to block any Congressional effort to extract cost savings from them beyond an agreed-upon $80 billion.

  • Animalistic Behavior Against Novartis Tuesday, 4 Aug 2009 | 2:38 PM ET

    Reports surfaced this morning that animal rights activists are suspected of setting fire to and badly damaging the vacation home of Novartis CEO Daniel Vasella in the wee hours of the morning yesterday.

  • Merck's First Or Only Shot? Monday, 3 Aug 2009 | 11:57 AM ET

    This Friday Merck and Schering-Plough shareholders are set to vote on the mega-merger. When companies co-mingle it's standard operating procedure for heads to roll. So-called "cost-saving synergies" are a big reason why deals like this get done. But this out-of-the-blue departure seems to have nothing to do with that.

  • Lack of Study Volunteers May Hobble Cancer Fight Monday, 3 Aug 2009 | 10:58 AM ET
    Cancer Treatment

    The biggest barrier to improved cancer treatments is that almost no adult cancer patients — just 3 percent — participate in studies of cancer treatments, mostly new drugs or drug regimens.

  • The Summer of Biotech Friday, 31 Jul 2009 | 4:21 PM ET
    Pharma Stocks

    Everyone’s talking about the July stock market rally. And, of course, you can’t overlook the outperformance of biotech—big and small.

  • Your Health Policy Has Been Canceled Tuesday, 28 Jul 2009 | 11:39 AM ET
    Healthcare coverage and the hastle of forms

    Government-run insurance could not be worse than what small businesses already face.

  • A Washington Drug Bust Monday, 27 Jul 2009 | 11:04 AM ET

    The drug companies help pay my salary. Not directly, of course (although I bet there are conspiracy theorists out there who are probably convinced they do), but they undoubtedly contribute a sizeable amount of advertising dollars to the company I work for.

  • Lilly's Side-Effect Slip-Up Thursday, 23 Jul 2009 | 3:33 PM ET

    I'm betting somebody's blood pressure at Eli Lilly headquarters in Indianapolis today went through the roof.

  • Biopharma Gets Its Groove On Thursday, 23 Jul 2009 | 1:42 PM ET

    What a week! And there's still one day left. Human Genome Sciences and Orexigen got the party started on Monday with their Lupus and diet drug data, respectively. Onyx Pharmaceuticals was a surprise guest with its mid-stage breast cancer results on Wednesday. Bristol-Myers Squibb cranked up the volume late yesterday with its two-bagger for Medarex. And then this morning Celgene announced it had stopped a multiple myeloma study early because the drug appears to be working so well.